Clinical Trial Search

Primary: Number of Gout Flares Per Subject — 3.02; 2.45 flares — p=0.1356

Primary: Resolution of the Acute Gout Attack — 15.4; 13.4 days — p=0.5

Primary: Change From Baseline to Day 2 in Patient's Assessment of Pain Intensity — 3.03; 2.73; 2.84; 2.83 Scores on a scale

Primary: Change in Pain Intensity — 3.5; 3.8 units on a scale

Primary: Number of Participants Who Reported Adverse Events — 78; 65; 64 Participants

Primary: Time to First New Flare — NA; NA Days

Primary: Responders — 17; 28; 9 Participants

Primary: Time to First New Flare: Survival Analysis During the 12 Weeks of Study — NA; NA Days

Primary: Number of Gout Flares Per Participant From Day 1 to Week 16 — 1.1; 0.3 gout flares

Primary: The Dose of Canakinumab for Treatment of Acute Flares in Gout Patients That Leads to the Same Efficacy as Triamcinolone Acetonide With Respect to Pain Intensity on a…

Primary: Pain Intensity on a 0-100 mm Visual Analog Scale (VAS) Between the Canakinumab 150 mg PFS and Triamcinolone Acetonide 40 mg Groups — 17.1; 32 Millimeters

Primary: Percentage of Participants Achieving Target Urate Levels (24 Weeks) — 29; 3 Participants

Primary: Preference IVR vs RheumPRO — 3; 28 Participants

Primary: Number and Percentage of Participants With Evidence of Chronic Ongoing Synovial-Based Inflammatory Disease at Baseline. — 63 Participants — p=0.34

Primary: Change From Baseline in Patient's Assessment of Pain Using a 5-Point Likert Scale (PAP-LS) in Index Joint to Averaged PAP-LS at 24, 48 and 72 Hours — -1.40; -1.55; -0.69…

Primary: Core Study: Mean Number of Gout Flares Per Participant — 0.5; 0.4; 0.2; 0.4 Gout flares

Primary: Proportion of Subjects Achieving Serum Uric Acid Concentration <6.0 mg/dL — 33; 43 Participants

Primary: Number of Participants With Adverse Events and Serious Adverse Events — 31; 52; 9; 15 Participants

Primary: Percentage of Participants With Improvement in Gout at 72 Hours Post-dose Using a Likert Scale — 100; 100 Percentage of participants

Primary: Number of Incidence Rate (IR) of Adverse Events, Serious Adverse Events and Death Per 100 Patient-years in Participants — 873; 451; 59; 25 IR/100 patient-years

Primary: Number of Gout Flares Per Participant Assessed From Day 1 to Day 84 (Week 12) — 0.79; 0.15 Number of gout flares per participant

Primary: Number of Gout Flares Per Participant Assessed From Day 1 to Day 113 (Week 16) — 1.23; 0.35; 0.34 Gout flares

Primary: sUA < 6.0 mg/dl at 1 Year — 117; 204 Participants

Primary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) — 59.1; 66.6; 13.0; 27.5 percentage of participants

Primary: Change in Patient-assessed Pain Intensity in the Index Joint From Baseline to 24-72 Hours for the First Gout Flare Treated in the Study as Measured by VAS — -26.1…

Primary: Mean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Erosion Score of the Single Affected Joint — 0.16; 0.11; 0.01; 0.01 score on a scale — p=0.472

Primary: Number of Gout Flares Per Participant Assessed From Day 1 to Day 112 (Week 16) — 1.06; 0.29; 0.21 Number of Gout flares per participant

Primary: Percentage of Participants Experiencing ≥ 1 Gout Flare During Phase 3 — 135; 165 Participants — p=<0.001

Primary: Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6 — 9.1 percentage of participants

Primary: Pulse Wave Velocity — 9.0; 9.05 m/s — p=0.5298